601607 上海医药
已收盘 01-09 15:00:00
资讯
新帖
简况
每周股票复盘：上海医药（601607）溴吡斯的明口服液获批生产
证券之星 · 01-11 03:20
每周股票复盘：上海医药（601607）溴吡斯的明口服液获批生产
上海医药：溴吡斯的明口服溶液获得批准生产
每日经济新闻 · 01-09 16:38
上海医药：溴吡斯的明口服溶液获得批准生产
每周股票复盘：云南白药（000538）预计2026年与上海医药关联交易达19亿元
证券之星 · 01-02
每周股票复盘：云南白药（000538）预计2026年与上海医药关联交易达19亿元
上海医药拟与云南白药续签关联交易协议，2026年双向交易额上限19亿元
中金财经 · 2025-12-31
上海医药拟与云南白药续签关联交易协议，2026年双向交易额上限19亿元
上海医药拟与云南白药续签19亿元上限关联交易协议，销售采购双向合作
财中社 · 2025-12-29
上海医药拟与云南白药续签19亿元上限关联交易协议，销售采购双向合作
上海医药拟续签云南白药框架协议 2026年销售上限12亿元、采购上限7亿元
美股速递 · 2025-12-29
上海医药拟续签云南白药框架协议 2026年销售上限12亿元、采购上限7亿元
上实集团财务公司股权变更获批 上海医药合计持股比例达40%
中国网财经 · 2025-12-29
上实集团财务公司股权变更获批 上海医药合计持股比例达40%
每周股票复盘：上海医药（601607）每股派现0.12元
证券之星 · 2025-12-28
每周股票复盘：上海医药（601607）每股派现0.12元
建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等
证券之星 · 2025-12-26
建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等
上海医药：每股派0.12元，股权登记日为12月31日
南方财经网 · 2025-12-24
上海医药：每股派0.12元，股权登记日为12月31日
上海医药成立智慧供应链科技公司
人民财讯 · 2025-12-24
上海医药成立智慧供应链科技公司
上海医药(601607.SH)：硫酸羟氯喹片获得菲律宾药品注册证书
智通财经 · 2025-12-15
上海医药(601607.SH)：硫酸羟氯喹片获得菲律宾药品注册证书
上海医药：盐酸索他洛尔片通过仿制药一致性评价
南方财经网 · 2025-12-15
上海医药：盐酸索他洛尔片通过仿制药一致性评价
上海医药：子公司取得药品上市许可
南方财经网 · 2025-12-10
上海医药：子公司取得药品上市许可
上海医药股东大会通过取消监事会及半年度分红等多项议案
中金财经 · 2025-12-10
上海医药股东大会通过取消监事会及半年度分红等多项议案
上海医药(02607)将于2026年2月6日派发中期股息每10股1.3215港元
智通财经 · 2025-12-09
上海医药(02607)将于2026年2月6日派发中期股息每10股1.3215港元
上海医药：氨磺必利口崩片纳入国家医保目录
人民财讯 · 2025-12-08
上海医药：氨磺必利口崩片纳入国家医保目录
上海医药：氨磺必利口崩片纳入国家医保目录 该药品境内暂无其他企业上市
每日经济新闻 · 2025-12-08
上海医药：氨磺必利口崩片纳入国家医保目录 该药品境内暂无其他企业上市
上海医药收回1.1亿元 终止与生诺生物新型抑酸剂合作
中国经营报 · 2025-12-07
上海医药收回1.1亿元 终止与生诺生物新型抑酸剂合作
历时4年终无果 上海医药终止与生诺生物合作协议
财中社 · 2025-12-05
历时4年终无果 上海医药终止与生诺生物合作协议
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.88,"timestamp":1767942001000,"preClose":17.84,"halted":0,"volume":13814169,"delay":0,"changeRate":0.0022,"floatShares":2789000000,"shares":3708000000,"eps":1.5224,"marketStatus":"已收盘","change":0.04,"latestTime":"01-09 15:00:00","open":17.85,"high":17.93,"low":17.82,"amount":247000000,"amplitude":0.0062,"askPrice":17.89,"askSize":483,"bidPrice":17.88,"bidSize":837,"shortable":0,"etf":0,"ttmEps":1.5224,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":17.84,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":19.62,"lowLimit":16.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.87,"roa":"--","peRate":11.744614,"roe":"6.96%","epsLYR":1.23,"committee":-0.417106,"marketValue":66306000000,"turnoverRate":0.005,"status":0,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.91,"timestamp":1767946115008,"preClose":11.87,"halted":0,"volume":2481800,"delay":0,"premium":"-40.48"},"floatMarketCap":49871000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2602744535","title":"每周股票复盘：上海医药（601607）溴吡斯的明口服液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2602744535","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602744535?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:20","pubTimestamp":1768072816,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，上海医药报收于17.88元，较上周的17.86元上涨0.11%。本周关注点公司公告汇总：溴吡斯的明口服溶液获国家药监局批准生产，国内尚无其他企业上市该品种。上海医药集团股份有限公司下属上海上药中西制药有限公司的溴吡斯的明口服溶液获得国家药品监督管理局批准生产，药品注册分类为化学药品3类，规格为473ml：5.676g，批准文号为国药准字H20256499。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","601607","BK0196","BK0012","02607","BK0175","BK0187","BK0028","BK0184","BK0020","BK0183","BK0188","BK0097","BK1197","BK0209"],"gpt_icon":0},{"id":"2602325106","title":"上海医药：溴吡斯的明口服溶液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2602325106","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602325106?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:38","pubTimestamp":1767947913,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月9日，上海医药(601607.SH)公告称，公司下属上海上药中西制药有限公司的溴吡斯的明口服溶液收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。溴吡斯的明口服溶液用于治疗重症肌无力，最早由BAUSCH公司研发，于1965年在美国上市。2024年4月，上药中西就该药品向国家药监局提出注册上市申请，并获受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601093614241842.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614241842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0209","BK0183","BK0020","BK0097","BK0187","BK0028","BK1197","601607","02607","BK0184","BK0196","BK0099","BK0012","BK0188"],"gpt_icon":0},{"id":"2600356870","title":"每周股票复盘：云南白药（000538）预计2026年与上海医药关联交易达19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600356870","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600356870?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:44","pubTimestamp":1767289454,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：云南白药预计2026年与上海医药日常关联交易总额为190,000.00万元。预计2026年与上海医药日常关联交易总额为190,000.00万元，占公司最近一期经审计净资产的4.89%，无需提交股东会审议。2025年实际发生关联交易总额为109,929.20万元，未超审批额度。关于2026年度预计日常关联交易的公告云南白药预计2026年度与上海医药发生日常关联交易总额为190,000.00万元，其中向其采购商品预计120,000.00万元，销售商品预计70,000.00万元，交易价格参照市场价格协商确定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601607","BK0164","BK0012","BK0175","BK0028","BK0187","BK0183","LU1993786604.SGD","BK0209","BK0097","BK0184","02607","LU1807302812.USD","LU1960683339.HKD","BK0188","BK1197","BK0196","BK0099","000538","BK0020"],"gpt_icon":1},{"id":"2595745414","title":"上海医药拟与云南白药续签关联交易协议，2026年双向交易额上限19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745414","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595745414?lang=zh_cn&edition=full","pubTime":"2025-12-31 08:05","pubTimestamp":1767139521,"startTime":"0","endTime":"0","summary":"中访网数据 上海医药集团股份有限公司于2025年12月29日召开董事会，审议通过了与关联方云南白药集团股份有限公司续签《日常关联交易/持续关连交易框架协议》的议案。根据协议，在2026年1月1日至2026年12月31日期间，上海医药向云南白药销售产品的金额上限为人民币12亿元，向云南白药采购产品的金额上限为人民币7亿元，双向交易总额上限合计19亿元。云南白药目前持有上海医药17.95%的股份，为其第二大股东，构成关联关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251231/31906320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0209","BK0184","BK0099","BK0196","LU1960683339.HKD","BK0164","BK0183","BK0028","000538","601607","BK0239","BK0187","BK0012","LU1993786604.SGD","BK0097","BK0020","LU1807302812.USD","BK1197","BK0175","02607"],"gpt_icon":0},{"id":"2595783594","title":"上海医药拟与云南白药续签19亿元上限关联交易协议，销售采购双向合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2595783594","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595783594?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:22","pubTimestamp":1766996528,"startTime":"0","endTime":"0","summary":"12月29日，上海医药（601607/02607）发布公告，公司拟与云南白药（000538）续签日常关联交易/持续关连交易框架协议。根据协议，2026年公司向云南白药销售产品金额上限为12亿元，向云南白药采购产品金额上限为7亿元。云南白药持有公司17.95%的股份，为公司第二大股东，是公司的关联方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604442415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1960683339.HKD","BK0164","BK0184","BK0183","BK0099","BK0239","BK0196","LU1993786604.SGD","LU1807302812.USD","02607","BK0097","BK1197","BK0187","BK0175","BK0012","BK0028","000538","BK0020","BK0209","BK0188","601607"],"gpt_icon":0},{"id":"1145701636","title":"上海医药拟续签云南白药框架协议 2026年销售上限12亿元、采购上限7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145701636","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145701636?lang=zh_cn&edition=full","pubTime":"2025-12-29 15:58","pubTimestamp":1766995115,"startTime":"0","endTime":"0","summary":"，中文，长度不超过4096字符，这里肯定没问题。检查是否符合所有要求：股票名称正确，关键信息保留，改写后流畅，有节奏感，无语法错误，中文表达自然。上海医药宣布，公司计划与云南白药续签框架协议。根据协议安排，2026年上海医药对云南白药的销售额上限将设定为12亿元，同期向云南白药的采购额上限则为7亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0099","BK0028","BK0020","BK0196","BK0012","BK0209","BK0184","BK0097","LU1960683339.HKD","BK0183","LU1807302812.USD","BK0175","BK0188","LU1993786604.SGD","000538","BK0164","601607","BK0187","BK0239"],"gpt_icon":0},{"id":"2595669201","title":"上实集团财务公司股权变更获批 上海医药合计持股比例达40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595669201","media":"中国网财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595669201?lang=zh_cn&edition=full","pubTime":"2025-12-29 13:20","pubTimestamp":1766985655,"startTime":"0","endTime":"0","summary":"中国网财经12月29日讯今日，上海金融监管局发布相关批复，同意上海医药集团股份有限公司(简称“上海医药”)受让上海实业东滩投资开发(集团)有限公司(简称“上实东滩”)持有的上海上实集团财务有限公司(简称“上实集团财务公司”)10%股权。受让后，上海医药合计持有上实集团财务公司40%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512293604337474.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604337474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0184","BK0209","BK0020","601607","BK0188","02607","BK0028","BK0183","BK0099","BK0196","BK0187","BK0097","BK0175","BK1197","BK0012"],"gpt_icon":0},{"id":"2594244029","title":"每周股票复盘：上海医药（601607）每股派现0.12元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244029?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:29","pubTimestamp":1766863750,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，上海医药报收于17.86元，较上周的18.03元下跌0.94%。12月24日盘中最低价报17.83元。上海医药当前最新总市值662.31亿元，在医药商业板块市值排名1/32，在两市A股市值排名267/5178。本周关注点公司公告汇总：上海医药2025年半年度每股派发现金红利0.12元（含税）。本次利润分配以公司总股本3,708,361,809股为基数，共派发现金红利445,003,417.08元，其中A股现金红利334,714,692.60元。A股股东的红利由中国结算上海分公司或公司自行发放，H股股东分红情况详见港交所公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0099","BK0187","BK0184","BK1197","BK0028","BK0012","BK0196","BK0175","601607","BK0209","BK0020","BK0183","BK0097","02607"],"gpt_icon":0},{"id":"2594263071","title":"建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2594263071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594263071?lang=zh_cn&edition=full","pubTime":"2025-12-26 11:36","pubTimestamp":1766720166,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司spd 系统，目前竞争对手有哪几家，份额占比多少建发致新回复：你好，尊敬的投资者。目前医疗器械SPD管理业务行业主要竞争对手有国药集团、上海医药、华润医药等医药商业企业，除此之外存在部分SPD专业管理公司如国医科技、德荣医疗、塞力医疗等。市场份额方面，根据部分市场报告显示，国药集团目前居于行业主导地位，其余公司呈现分散竞争的格局。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600012621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","09996","03320","BK1100","601607","BK1570","301584","BK0097","159883","BK0020","02607","BK0184","BK0183","BK1583","BK0209","BK0187","BK0012","BK0099","BK1574","BK0028","BK1191","BK0250","BK1197","BK0175","BK1222","09997"],"gpt_icon":0},{"id":"2593475405","title":"上海医药：每股派0.12元，股权登记日为12月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475405","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475405?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:46","pubTimestamp":1766569605,"startTime":"0","endTime":"0","summary":"南财智讯12月24日电，上海医药发布2025年半年度权益分派实施公告，本次利润分配方案经公司2025年第二次临时股东大会审议通过。本次利润分配以方案实施前的公司总股本为基数，每股派发现金红利0.12元（含税），共计派发现金红利4.45亿元。截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司登记在册的本公司全体A股股东均可参与本次分红。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600829478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0020","BK0097","BK0187","BK0188","BK0196","BK1197","02607","BK0099","BK0184","BK0175","BK0012","601607","BK0028","BK0209"],"gpt_icon":0},{"id":"2593424531","title":"上海医药成立智慧供应链科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593424531","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593424531?lang=zh_cn&edition=full","pubTime":"2025-12-24 14:36","pubTimestamp":1766558186,"startTime":"0","endTime":"0","summary":"人民财讯12月24日电，企查查APP显示，近日，上药智慧供应链科技（上海）有限公司成立，法定代表人为任刚，注册资本为2000万元，经营范围包含：智能控制系统集成；人工智能应用软件开发；人工智能行业应用系统集成服务；供应链管理服务等。企查查股权穿透显示，该公司由上海医药间接全资持股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600647829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0184","BK0209","BK0012","BK0188","601607","BK1197","BK0183","BK0028","BK0097","BK0187","BK0196","BK0175","02607","BK0099","BK0020"],"gpt_icon":0},{"id":"2591616417","title":"上海医药(601607.SH)：硫酸羟氯喹片获得菲律宾药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616417","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616417?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:09","pubTimestamp":1765786182,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药中西制药有限公司(简称“上药中西”)生产的硫酸羟氯喹片收到菲律宾食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。硫酸羟氯喹片主要用于类风湿关节炎、青少年慢性关节炎、盘状和系统性红斑狼疮、以及由阳光引发或加剧的皮肤疾病。本次硫酸羟氯喹片(200mg)获得菲律宾食品药品监督管理局的药品注册批文，标志着公司具备了在菲律宾市场销售该药品的资格，对公司拓展海外市场带来积极影响，并积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","BK0012","BK0097","BK0028","BK0187","BK0188","BK0099","BK1197","BK0183","BK0184","BK0196","BK0020","BK0209","02607","BK0175"],"gpt_icon":0},{"id":"2591616286","title":"上海医药：盐酸索他洛尔片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616286","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616286?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:05","pubTimestamp":1765785951,"startTime":"0","endTime":"0","summary":"【上海医药：盐酸索他洛尔片通过仿制药一致性评价】上海医药公告，常州制药厂有限公司收到国家药监局颁发的《药品补充申请批准通知书》，盐酸索他洛尔片通过仿制药质量和疗效一致性评价。该药品主要用于转复和预防室上性心动过速、心房扑动、心房颤动、各种室性心律失常以及急性心肌梗死并发严重心律失常。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591706790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","02607","BK0097","BK0020","BK0175","BK0209","BK0184","BK1197","BK0183","BK0099","BK0196","601607","BK0012","BK0187","BK0028"],"gpt_icon":0},{"id":"2590301278","title":"上海医药：子公司取得药品上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2590301278","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590301278?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:53","pubTimestamp":1765353188,"startTime":"0","endTime":"0","summary":"南财智讯12月10日电，上海医药公告，公司下属上海上药信谊药厂有限公司收到国家药品监督管理局下发的《药品注册证书》，其提交的苹果酸司妥吉仑片（即SPH3127片）的药品上市许可申请已获批准。该药品为化学药品1类，适用于原发性高血压的治疗，相关项目累计已投入研发费用约2.96亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587664274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0099","BK0187","BK0184","BK1197","BK0028","BK0012","BK0196","BK0175","601607","BK0209","BK0020","BK0183","BK0097","02607"],"gpt_icon":0},{"id":"2590308537","title":"上海医药股东大会通过取消监事会及半年度分红等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2590308537","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590308537?lang=zh_cn&edition=full","pubTime":"2025-12-10 13:17","pubTimestamp":1765343821,"startTime":"0","endTime":"0","summary":"中访网数据 上海医药集团股份有限公司于2025年12月9日召开2025年第二次临时股东大会。会议以现场结合网络投票方式审议并通过了全部四项议案。其中，关于取消监事会并修订《公司章程》及其附件的特别决议案获得高票通过，同意股份数占出席会议有效表决权股份总数的95.78%，远超三分之二门槛。此举意味着公司治理结构将从“三会一层”向“董事会中心”模式转变。备受关注的2025年半年度利润分配预案也获批准，同意票比例高达99.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31855866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0099","BK0020","BK0097","BK0188","BK0209","BK0184","601607","BK0012","BK1197","BK0175","BK0028","BK0196","BK0183","02607","BK0187"],"gpt_icon":0},{"id":"2590312678","title":"上海医药(02607)将于2026年2月6日派发中期股息每10股1.3215港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312678","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590312678?lang=zh_cn&edition=full","pubTime":"2025-12-09 18:04","pubTimestamp":1765274665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)公布，将于2026年2月6日派发中期股息每10股1.3215港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1197","BK0187","BK0012","BK0188","BK0097","BK0183","BK0209","BK0020","BK0184","BK0099","BK0175","BK0028","601607","02607"],"gpt_icon":0},{"id":"2589389393","title":"上海医药：氨磺必利口崩片纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389393","media":"人民财讯","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589389393?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:02","pubTimestamp":1765180968,"startTime":"0","endTime":"0","summary":"人民财讯12月8日电，上海医药(601607)12月8日公告，公司下属公司上药中西的氨磺必利口崩片通过国家医保谈判，成功纳入《国家医保目录》。氨磺必利口崩片是赛诺菲（Sanofi）公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人精神分裂症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585282351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0020","BK0097","BK0187","BK0188","BK0196","BK1197","02607","BK0099","BK0184","BK0175","BK0012","601607","BK0028","BK0209"],"gpt_icon":0},{"id":"2589233893","title":"上海医药：氨磺必利口崩片纳入国家医保目录 该药品境内暂无其他企业上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2589233893","media":"每日经济新闻","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589233893?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:58","pubTimestamp":1765180734,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月8日，上海医药(601607.SH)公告称，公司下属上海上药中西制药有限公司的氨磺必利口崩片通过国家医保谈判，成功纳入《国家医保目录》，协议有效期为自2026年1月1日至2027年12月31日。截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市。IQVIA数据库显示，2024年氨磺必利口服制剂的医院采购金额为1.68亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512083585276022.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585276022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","02607","BK0188","601607","BK0099","BK0028","BK0187","BK0209","BK0020","BK0183","BK0184","BK0196","BK0012","BK0097","BK1197"],"gpt_icon":0},{"id":"2589087717","title":"上海医药收回1.1亿元 终止与生诺生物新型抑酸剂合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2589087717","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589087717?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:30","pubTimestamp":1765114201,"startTime":"0","endTime":"0","summary":"12月5日晚间，上海医药（601607.SH）发布公告，宣布其全资子公司上海上药信谊药厂有限公司（以下简称“上药信谊”）已正式终止与贵州生诺生物科技有限公司及其关联方关于新型抑酸剂X842项目的合作协议。根据双方签署的终止协议，贵州生诺方面已返还上海医药1.1亿元首付款及开发注册里程碑费用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584625889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK0187","BK0099","BK0184","BK0012","BK0188","BK0028","BK0196","BK1197","BK0183","BK0020","BK0209","BK0175","601607","BK0097"],"gpt_icon":0},{"id":"2589860452","title":"历时4年终无果 上海医药终止与生诺生物合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860452","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589860452?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:52","pubTimestamp":1764924759,"startTime":"0","endTime":"0","summary":"12月5日，上海医药（601607/02607）发布公告，宣布与贵州生诺生物科技有限公司的合作协议终止。该协议于2021年10月8日签署，涉及新型抑酸剂X842项目，允许公司全资子公司上药信谊获得该项目的独家生产和销售权。基于对外部市场的综合评估及各方经营发展规划的考虑，2025年11月18日，上药信谊与生诺生物达成了终止协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053583869660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0099","601607","BK0020","02607","BK0097","BK0187","BK0196","BK0175","BK0183","BK1197","BK0012","BK0028","BK0188","BK0184","BK0209"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768154459521,"stockEarnings":[{"period":"1week","weight":0.0079},{"period":"1month","weight":0.0142},{"period":"3month","weight":-0.0201},{"period":"6month","weight":-0.0379},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":0.0079}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}